Johnson & Johnson (NYSE:JNJ) Shares Down 1.3% - What's Next?

Johnson & Johnson (NYSE:JNJ - Get Free Report)'s stock price fell 1.3% during mid-day trading on Tuesday . The company traded as low as $152.05 and last traded at $152.75. 1,299,642 shares traded hands during mid-day trading, a decline of 81% from the average session volume of 6,993,952 shares. The stock had previously closed at $154.77.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on JNJ. Wells Fargo & Company lifted their price objective on Johnson & Johnson from $163.00 to $166.00 and gave the company an "equal weight" rating in a report on Wednesday, October 16th. StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, September 14th. Wolfe Research assumed coverage on Johnson & Johnson in a report on Friday. They set an "outperform" rating and a $190.00 price target for the company. Morgan Stanley increased their target price on Johnson & Johnson from $169.00 to $175.00 and gave the stock an "equal weight" rating in a research note on Wednesday, October 16th. Finally, Royal Bank of Canada upped their target price on Johnson & Johnson from $178.00 to $181.00 and gave the company an "outperform" rating in a research report on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $175.94.

Johnson & Johnson Stock Performance

The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The business's fifty day simple moving average is $161.11 and its 200-day simple moving average is $156.16. The firm has a market cap of $367.40 billion, a P/E ratio of 22.11, a price-to-earnings-growth ratio of 2.74 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating analysts' consensus estimates of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. During the same quarter last year, the firm earned $2.66 earnings per share. The business's revenue for the quarter was up 5.2% on a year-over-year basis. As a group, sell-side analysts expect that Johnson & Johnson will post 9.93 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.25%. Johnson & Johnson's payout ratio is currently 71.78%.

Insider Buying and Selling at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the sale, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. This represents a 22.90 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 0.16% of the company's stock.

Institutional Trading of Johnson & Johnson

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Innealta Capital LLC purchased a new position in shares of Johnson & Johnson during the second quarter valued at $27,000. Highline Wealth Partners LLC bought a new stake in shares of Johnson & Johnson in the 3rd quarter valued at about $31,000. RPg Family Wealth Advisory LLC purchased a new stake in shares of Johnson & Johnson in the 3rd quarter worth approximately $35,000. Mowery & Schoenfeld Wealth Management LLC boosted its stake in shares of Johnson & Johnson by 58.7% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company's stock valued at $40,000 after purchasing an additional 91 shares in the last quarter. Finally, Activest Wealth Management bought a new position in Johnson & Johnson in the third quarter worth approximately $40,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.